Analytical Data
-
Gene name
GRIA3
- Application
-
Alternative Names
GRIA3；GluA3；GLUR3；GLURC；Glutamate receptor 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P42263
-
Expression Region
151-250aa
-
AA Sequence
SLLGHYKWEKFVYLYDTERGFSILQAIMEAAVQNNWQVTARSVGNIKDVQEFRRIIEEMDRRQEKRYLIDCEVERINTILEQVVILGKHSRGYHYMLANL
-
Molecular Weight
14.0kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRIA3, a member of the glutamate receptor family, plays a critical role in synaptic transmission and plasticity within the central nervous system, particularly in mediating excitatory neurotransmission. Its involvement in various neurophysiological processes makes it a significant target for understanding neurological disorders, including epilepsy, schizophrenia, and neurodegenerative diseases. Research has shown that alterations in GRIA3 expression or function can contribute to the pathological mechanisms underlying these conditions. Recombinant GRIA3 protein studies are essential for elucidating its specific functional properties, interactions with other proteins, and regulatory mechanisms. By producing and characterizing recombinant GRIA3, researchers can dissect its role in synaptic function and signal transduction pathways. Additionally, this research facilitates the development of potential therapeutic strategies aimed at modulating GRIA3 activity, which could lead to novel treatments for related neurological disorders. Thus, the study of GRIA3 recombinant protein is not only fundamental for basic neuroscience but also holds promise for advancing our understanding of various brain disorders and developing targeted pharmacological interventions.
